TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

When was the last time you thought about your lungs unless you were short of breath or down with a cold? Most of us take our lungs for granted, but these spongy, hard-working organs do a lot more than ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Timing the use of a commonly prescribed asthma inhaler in the mid-afternoon could lead to improved clinical outcomes, ...

The global aerosol delivery devices market was valued at $31,463.9 million in 2019, and is projected to reach $46,728.7 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Rise in ...

BAKU, Azerbaijan, April 18. Trend News Agency presents an interview with Azerbaijani physician Khavar Musayeva, a specialist ...

Recognizing when to seek medical attention can be a stressful and challenging decision, but it is one of the most crucial ...

A condition like pneumonia, COPD, or asthma There ... it's important to discuss your treatment options with a healthcare provider. Do not attempt to self-treat infections or other serious conditions ...

Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...